Patients with inflammatory bowel disease (IBD) are at increased risk of thrombotic events.
Therapies for IBD have the potential to modulate this risk. The aims of this Evidence-Based …

Objective We aimed to provide an evidence-supported update of the ECCO-ESPGHAN
guideline on the medical management of paediatric Crohn's disease [CD]. Methods We …

Background The efficacy and safety of vedolizumab in bio-naïve patients with ulcerative
colitis (UC) and Crohn's disease (CD) remain unknown. Aims To perform a meta-analysis …

METHODS: Clinical response, remission, and steroid-free remission at weeks 26 and 52
were evaluated in a retrospective propensity score–weighted and propensity score …

Immune checkpoint inhibitors are a novel class of cancer treatment that have improved
outcomes for a subset of cancer patients. They work by antagonising inhibitory immune …

Abstract Background and Aims Many observational studies on the use of vedolizumab [VDZ]
in patients with Crohn's disease [CD] and ulcerative colitis [UC] have been published in the …

Inflammatory bowel disease (IBD) is a lifelong inflammatory immune mediated disorder,
encompassing Crohn's disease (CD) and ulcerative colitis (UC); however, the cause and …

Background: Prospectively and systematically collected real-world data on vedolizumab are
scarce. We aimed to assess the long-term clinical effectiveness of vedolizumab in …

Background Biologically naïve patients with inflammatory bowel disease treated with
vedolizumab (VDZ) are largely underrepresented in real-world cohorts. A multi-centre …

Abstract Background and Objectives Vedolizumab has demonstrated efficacy and safety in
patients with Crohn's disease [CD] and ulcerative colitis [UC]. Endoscopic outcome data are …